0.8814
price down icon3.14%   -0.0286
pre-market  시장 영업 전:  .92   0.0386   +4.38%
loading

Renovorx Inc 주식(RNXT)의 최신 뉴스

pulisher
Apr 06, 2025

HC Wainwright Reaffirms “Buy” Rating for RenovoRx (NASDAQ:RNXT) - Defense World

Apr 06, 2025
pulisher
Apr 04, 2025

H.C. Wainwright maintains Buy rating on RenovoRx stock By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

H.C. Wainwright maintains Buy rating on RenovoRx stock - Investing.com Australia

Apr 04, 2025
pulisher
Apr 04, 2025

Revolutionary Pancreatic Cancer Treatment Update: RenovoRx CEO Presents Latest Clinical Trial Results - Stock Titan

Apr 04, 2025
pulisher
Apr 01, 2025

RenovoRx Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 01, 2025
pulisher
Apr 01, 2025

RenovoRx projects growth with new orders and clinical trial - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

RenovoRx Hits Major Milestone: First Revenue from Cancer Device as Phase 3 Trial Nears Key Analysis - Stock Titan

Apr 01, 2025
pulisher
Apr 01, 2025

RenovoRx, Inc. SEC 10-K Report - TradingView

Apr 01, 2025
pulisher
Mar 31, 2025

RenovoRx Delays Yearly Report Filing - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial - Business Wire

Mar 31, 2025
pulisher
Mar 31, 2025

RenovoRx (RNXT) to Release Earnings on Monday - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

HC Wainwright Estimates RenovoRx FY2024 Earnings - Defense World

Mar 31, 2025
pulisher
Mar 28, 2025

RenovoRx Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting - BioSpace

Mar 28, 2025
pulisher
Mar 28, 2025

Breakthrough: RenovoRx's Pancreatic Cancer Treatment Shows Promise with Reduced Systemic Exposure - Stock Titan

Mar 28, 2025
pulisher
Mar 28, 2025

RenovoRx (NASDAQ:RNXT) Coverage Initiated by Analysts at HC Wainwright - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

HC Wainwright & Co. Initiates Coverage of RenovoRx (RNXT) with Buy Recommendation - Nasdaq

Mar 27, 2025
pulisher
Mar 27, 2025

HC Wainwright Initiates Coverage on RenovoRx With Buy Rating, $3 Price Target - MarketScreener

Mar 27, 2025
pulisher
Mar 26, 2025

RenovoRx honored for cancer treatment research By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting - BioSpace

Mar 26, 2025
pulisher
Mar 26, 2025

RenovoRx honored for cancer treatment research - Investing.com

Mar 26, 2025
pulisher
Mar 25, 2025

RenovoRx (NASDAQ:RNXT) Stock Price Up 11.5% – Should You Buy? - Defense World

Mar 25, 2025
pulisher
Mar 20, 2025

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET - Business Wire

Mar 20, 2025
pulisher
Mar 20, 2025

RenovoRx Reveals Commercial Milestones and Phase 3 Trial Updates for Revolutionary Pancreatic Cancer Treatment - Stock Titan

Mar 20, 2025
pulisher
Mar 19, 2025

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025 - Business Wire

Mar 19, 2025
pulisher
Mar 15, 2025

RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026 - Business Wire

Mar 15, 2025
pulisher
Feb 26, 2025

RenovoRx launches public stock offering - MSN

Feb 26, 2025
pulisher
Feb 26, 2025

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders - BioSpace

Feb 26, 2025
pulisher
Feb 26, 2025

with Several New Purchase Orders, Including Customer Reorders - Business Wire

Feb 26, 2025
pulisher
Feb 26, 2025

Can RenovoRx's Premium-Priced Cancer Device Deliver on its $400M Market Potential? - Stock Titan

Feb 26, 2025
pulisher
Feb 14, 2025

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery - BioSpace

Feb 14, 2025
pulisher
Feb 12, 2025

RenovoRx Announces $10.9 Million Public Offering of Common Stock - Defense World

Feb 12, 2025
pulisher
Feb 11, 2025

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock - Business Wire

Feb 11, 2025
pulisher
Feb 11, 2025

RenovoRx (RNXT) Lands Major $12.1M Healthcare Investor Backing for Cancer Treatment Launch - Stock Titan

Feb 11, 2025
pulisher
Feb 10, 2025

A better buy-in window may exist right now for RenovoRx Inc (RNXT) - SETE News

Feb 10, 2025
pulisher
Feb 10, 2025

Closing Figures: RenovoRx Inc (RNXT)’s Negative Finish at 1.16, Down -20.55 - The Dwinnex

Feb 10, 2025
pulisher
Feb 10, 2025

Trading Day Review: Unicycive Therapeutics Inc (UNCY) Loses Momentum, Closing at 0.57 - The Dwinnex

Feb 10, 2025
pulisher
Feb 10, 2025

RenovoRx Inc (RNXT) Stock: A Year of Decreases and Increases - The InvestChronicle

Feb 10, 2025
pulisher
Feb 10, 2025

RenovoRx Inc (RNXT) Stock: Tracking the Weekly Performance - The News Heater

Feb 10, 2025
pulisher
Feb 08, 2025

RenovoRx 11.52M share Spot Secondary priced at $1.05 - MSN

Feb 08, 2025
pulisher
Feb 08, 2025

RenovoRx (NASDAQ:RNXT) Stock Price Down 20.5% – Should You Sell? - Defense World

Feb 08, 2025
pulisher
Feb 07, 2025

RenovoRx announces proposed public offering - MSN

Feb 07, 2025
pulisher
Feb 07, 2025

RenovoRx Prices $12.1 Million Public Offering; Shares Decline Po - GuruFocus.com

Feb 07, 2025
pulisher
Feb 07, 2025

RenovoRx Prices $12.1 Million Public Offering; Shares Decline Post-Announcement - Yahoo Finance

Feb 07, 2025
pulisher
Feb 07, 2025

RenovoRx prices public offering to raise $12.1M - MSN

Feb 07, 2025
pulisher
Feb 07, 2025

RenovoRx launches public stock offering By Investing.com - Investing.com Nigeria

Feb 07, 2025
pulisher
Feb 06, 2025

RenovoRx Announces Pricing Of Public Offering Of About 11.52 Million Shares At $1.05/shr - Nasdaq

Feb 06, 2025
pulisher
Feb 06, 2025

RenovoRx Secures Critical $12.1M Funding: Phase III Cancer Study Gets Green Light - StockTitan

Feb 06, 2025
pulisher
Feb 06, 2025

Renovorx Announces Pricing Of $12.1 Million Underwritten Public Offering Of Common Stock - Marketscreener.com

Feb 06, 2025
pulisher
Feb 06, 2025

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock - Business Wire

Feb 06, 2025
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
자본화:     |  볼륨(24시간):